Genomics BioSci & Tech (基米) reported record annual revenue of NT$708 million (+36.86% YoY) for 2025. General Manager Chiang Chun-chi noted that the company’s transition from a research-focused service to a clinical and industrial provider is yielding significant results.

Key Strategic Milestones:

• Clinical Diagnostics (LDTs): Genomics BioSci & Tech secured 9 new LDTs certifications in 2025, bringing its total to 10. This positions the company at the industry forefront for WGS (Whole Genome Sequencing) and WES (Whole Exome Sequencing), aligning with Taiwan’s National Health Insurance (NHI) reimbursement trends for NGS.
• Industrial Diversification: The instrumentation department now accounts for 28.15% of revenue, with active efforts to secure orders from the semiconductor and electronics sectors.
• Regional Hub: Genomics BioSci & Tech is expanding its footprint in Indonesia, the Philippines, Australia, Malaysia, and Thailand. In collaboration with Illumina, Genomics BioSci & Tech aims to become a premier multi-omics service hub in the Asia-Pacific region.

Resource: 多元轉型發酵＋海外市場助攻 基米2026年業績看俏